Tizanidne Hydrochloride Capsule
Product Images NDC 71335-2209

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 71335-2209). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352209)

Label for Tizanidine Hydrochloride Capsules 4 mg by Bryant Ranch Prepack. The label states each capsule contains 4.58 mg Tizanidine Hydrochloride equivalent to 4 mg Tizanidine base. The package contains 150 capsules. Manufactured by Alkem Laboratories Ltd. Storage instructions and a warning about non-interchangeability with certain tablets are included.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure of tizanidine hydrochloride, showing a chlorinated benzene ring fused to heterocyclic rings containing nitrogen and sulfur atoms, with an attached imidazoline moiety.*

FDA Label Image

Tiz02 (Tiz02)

A pharmacokinetic graph showing plasma tizanidine concentration (ng/mL) over 24 hours post dosing, comparing 4 mg tizanidine tablets and capsules taken with and without food. The chart displays curves for each condition, illustrating concentration changes over time from 0 to 24 hours.*

FDA Label Image

Tiz03 (Tiz03)

A line graph showing improvement in Ashworth Score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis represents improvement (negative values) and the horizontal axis shows hours from 0 to 6. Both tizanidine doses show increased improvement compared to placebo, peaking around 2 to 3 hours post-dose, then declining toward 6 hours.*

FDA Label Image

Tiz04 (Tiz04)

A line graph showing improvement in Ashworth Score over time for two groups: tizanidine (mean dose 28.8 mg) and placebo. The x-axis marks three study time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The y-axis shows improvement scores ranging from -6 to 2, with tizanidine showing consistent improvement below 0 and placebo near or above 0, including error bars at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.